• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form POS AM filed by Viveve Medical Inc.

    1/26/23 8:56:27 PM ET
    $VIVE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $VIVE alert in real time by email
    POS AM 1 vive20230125f_posam.htm FORM POS AM vive20230125f_posam.htm

    As filed with the Securities and Exchange Commission on January 26, 2023.

    Registration No. 333-257648



     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     


     

    POST-EFFECTIVE AMENDMENT NO. 1 TO:

    Form S-3 Registration No. 333-257648

    UNDER THE SECURITIES ACT OF 1933

     


     

    VIVEVE MEDICAL, INC.

    (Exact name of registrant as specified in its charter)

     


     

    Delaware

     

    04-3153858

    (State or other jurisdiction of incorporation or organization)

     

    (IRS Employer Identification No.)

     

    345 Inverness Drive South

    Building B, Suite 250

    Englewood, CO 80112

    Telephone: (720) 696-8100

    (Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)

     


    Scott Durbin
    345 Inverness Drive South
    Building B, Suite 250
    Englewood, CO 80112
    Telephone: (720) 696-8100
    (Name, address, including zip code and telephone number, including area code, of agent for service)

     


     

    Copies to:

     

    Mitchell S. Bloom, Esq.

    Shoaib Ghias, Esq.

    Goodwin Procter LLP

    Three Embarcadero Center

    San Francisco, CA 94111

    (415) 733-6000

     



     

    Approximate date of commencement of proposed sale to the public: This post-effective amendment is being filed to deregister all of the unsold securities previously registered under the Registration Statement.

     

     

     

     

    If the only securities being registered on this Form are being offered pursuant to dividend or interest reinvestment plans, please check the following box: ☐

     

    If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, other than securities offered only in connection with dividend or interest reinvestment plans, check the following box: ☐

     

    If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

     

    If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

     

    If this Form is a registration statement pursuant to General Instruction I.D. or a post-effective amendment thereto that shall become effective upon filing with the Commission pursuant to Rule 462(e) under the Securities Act, check the following box. ☐

     

    If this Form is a post-effective amendment to a registration statement filed pursuant to General Instruction I.D. filed to register additional securities or additional classes of securities pursuant to Rule 413(b) under the Securities Act, check the following box. ☐

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer

     

    ☐

     

    Accelerated filer

     

    ☐

    Non-accelerated filer

     

    ☒

     

    Smaller reporting company

     

    ☒

           

    Emerging growth company

     

    ☐

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided to Section 7(a)(2)(B) of the Securities Act. ☐

     

     

     

     

    DEREGISTRATION OF SECURITIES

     

    This Post-Effective Amendment No. 1 relates to the following Registration Statement on Form S-3 (the “Registration Statement”), filed with the Securities Exchange Commission (the “SEC”) by Viveve Medical, Inc. (the “Registrant”):

     

     

    •

    Registration Statement No. 333-257648, originally filed with the SEC on July 2, 2021, as amended by Amendment No. 1 on September 23, 2022.

     

    The Registrant is filing this Post-Effective Amendment to deregister any and all securities that remain unsold under the Registration Statement as of the date hereof. In accordance with the undertakings made by the Registrant in the Registration Statement to remove from registration by means of a post-effective amendment any securities that had been registered for issuance but remain unsold at the termination of the offering, the Registrant hereby removes and withdraws from registration any and all securities registered pursuant to the Registration Statement that remain unsold as of the date hereof.

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-3 and has duly caused this Post-Effective Amendment to the Registration Statement on Form S-3 to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Englewood, State of Colorado, on January 26, 2023.

     

     

    VIVEVE MEDICAL, INC. 

     
           
     

    By:

    /s/ Scott Durbin

     
       

    Scott Durbin, Chief Executive Officer  

     

     

    No other person is required to sign this Post-Effective Amendment in reliance upon Rule 478 under the Securities Act of 1933.

     

     
    Get the next $VIVE alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $VIVE

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $VIVE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Basta Steven L

    4 - VIVEVE MEDICAL, INC. (0000879682) (Issuer)

    1/5/23 4:04:01 PM ET
    $VIVE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 4 filed by Durbin Scott

    4 - VIVEVE MEDICAL, INC. (0000879682) (Issuer)

    1/5/23 4:03:31 PM ET
    $VIVE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 4 filed by Jorn Debora

    4 - VIVEVE MEDICAL, INC. (0000879682) (Issuer)

    1/5/23 4:03:15 PM ET
    $VIVE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $VIVE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Alliance Global Partners initiated coverage on Viveve Medical

    Alliance Global Partners initiated coverage of Viveve Medical with a rating of Buy

    1/30/21 7:59:20 PM ET
    $VIVE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Alliance Global Partners initiated coverage on Viveve Medical with a new price target

    Alliance Global Partners initiated coverage of Viveve Medical with a rating of Buy and set a new price target of $10.75

    1/29/21 7:09:51 AM ET
    $VIVE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $VIVE
    SEC Filings

    View All

    SEC Form 15-12G filed by Viveve Medical Inc.

    15-12G - VIVEVE MEDICAL, INC. (0000879682) (Filer)

    2/6/23 4:02:17 PM ET
    $VIVE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form EFFECT filed by Viveve Medical Inc.

    EFFECT - VIVEVE MEDICAL, INC. (0000879682) (Filer)

    1/31/23 12:15:28 AM ET
    $VIVE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form EFFECT filed by Viveve Medical Inc.

    EFFECT - VIVEVE MEDICAL, INC. (0000879682) (Filer)

    1/31/23 12:15:10 AM ET
    $VIVE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $VIVE
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Viveve Announces Topline Results from Pivotal U.S. PURSUIT Trial for Treating Female Stress Urinary Incontinence

    Study's primary efficacy endpoint was not achieved at 12 months post-treatmentCompany has implemented a reduction in forceCompany will seek strategic alternatives and will be delisted from Nasdaq ENGLEWOOD, CO / ACCESSWIRE / January 17, 2023 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's health and the treatment of female stress urinary incontinence (SUI), today announced topline result from the U.S. Pivotal PURSUIT clinical trial. PURSUIT was a multicenter, randomized, double-blinded, sham-controlled U.S. study to evaluate the safety and efficacy of the Viveve treatment for SUI in women. The results were obtained by the company on Friday evening, Janu

    1/17/23 6:30:00 AM ET
    $VIVE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Viveve Announces Completion of Pivotal US PURSUIT Trial for Female Stress Urinary Incontinence with Final 12-month Follow-up Visits Concluded

    Topline results of the 12-month primary efficacy endpoint anticipated in January 2023Positive results may support a de novo marketing application for a new U.S. indication for treatment of stress urinary incontinence in womenENGLEWOOD, CO / ACCESSWIRE / December 15, 2022 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's health and treatment of female stress urinary incontinence, today announced the completion of final 12-month post-treatment follow-up visits in its landmark U.S. PURSUIT clinical trial for the treatment of stress urinary incontinence (SUI) in women. A total of 415 patients were enrolled in the trial, and 342 patients completed 12-month foll

    12/15/22 8:28:00 AM ET
    $VIVE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Viveve Announces Issuance of Second U.S. Method Patent for Treating Female Stress Urinary Incontinence

    Patent further strengthens Viveve's novel dual-energy technology intellectual property portfolio as company plans for completion of pivotal PURSUIT clinical trialENGLEWOOD, CO / ACCESSWIRE / December 1, 2022 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's health and the treatment of female stress urinary incontinence (SUI), today announced the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 11511110 covering Viveve's treatment to address SUI in women. The issuance of the new patent strengthens the Company's intellectual property portfolio in advance of the planned completion of its U.S. pivotal PURSUIT clinical trial by the e

    12/1/22 8:28:00 AM ET
    $VIVE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $VIVE
    Financials

    Live finance-specific insights

    View All

    Viveve Reports Third Quarter 2022 Financial Results and Provides Corporate Update

    Total revenue of $1.7 million in Q3 including sale of 3,100 disposable treatment tipsPURSUIT clinical trial completion expected by year-endConference call to be hosted by Company at 5:00 PM ET todayENGLEWOOD, CO / ACCESSWIRE / November 10, 2022 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's health and the treatment of female stress urinary incontinence (SUI), today reported financial results for the quarter ended September 30, 2022, and will provide a corporate update on its scheduled conference call at 5:00 PM ET today."During the third quarter of 2022, we continued to make great progress in the final phase of our pivotal U.S. PURSUIT clinical trial fo

    11/10/22 4:02:00 PM ET
    $VIVE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Viveve to Report Third Quarter 2022 Financial Results and Provide Corporate Update on November 10, 2022

    ENGLEWOOD, CO / ACCESSWIRE / October 27, 2022 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's health and the treatment of stress urinary incontinence (SUI), today announced that it will report its third quarter 2022 financial results and provide a corporate update after the close of the U.S. financial markets on Thursday, November 10, 2022. The Company will hold a conference call and webcast at 5:00 PM ET the same day.The third quarter 2022 results conference call may be accessed on Thursday, November 10th at 5:00 PM ET by dialing 1-833-255-2833 (domestic) or 1-412-902-6728 (international) or via live webcast at https://event.choruscall.com/mediaframe/we

    10/27/22 8:28:00 AM ET
    $VIVE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Viveve Reports Second Quarter 2022 Financial Results and Provides Corporate Update

    Total revenue of $1.8 million in Q2 including sale of 2,850 disposable treatment tipsPURSUIT clinical trial follow-up visit completion anticipated by year endConference call to be hosted by Company at 5:00 PM ET todayENGLEWOOD, CO / ACCESSWIRE / August 11, 2022 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's health and the treatment of stress urinary incontinence (SUI), today reported financial results for the quarter ended June 30, 2022, and will provide a corporate update on its scheduled conference call at 5:00 PM ET today."During the second quarter of 2022, we continued to advance our stress urinary incontinence (SUI) clinical development program. We

    8/11/22 4:01:00 PM ET
    $VIVE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $VIVE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Viveve Medical Inc. (Amendment)

    SC 13G/A - VIVEVE MEDICAL, INC. (0000879682) (Subject)

    2/4/22 4:17:42 PM ET
    $VIVE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form SC 13G/A filed by Viveve Medical Inc. (Amendment)

    SC 13G/A - VIVEVE MEDICAL, INC. (0000879682) (Subject)

    1/18/22 11:21:09 AM ET
    $VIVE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form SC 13G/A filed

    SC 13G/A - VIVEVE MEDICAL, INC. (0000879682) (Subject)

    2/16/21 11:21:31 AM ET
    $VIVE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care